米多君治疗直立性低血压

Midodrine in treatment of orthostatic hypotension

目的 :研究米多君对直立性低血压的有效性及安全性。方法 :采用开放性试验对 2 9例原发性和继发性直立性低血压病人给予口服米多君 5～7.5mg·d- 1治疗 ,疗程 5wk。结果 :可评估 2 8例病人 ,接受米多君治疗 5wk ,头晕、头昏症状明显改善(P <0 .0 1) ,立位收缩血压与治疗前比较均有上升 ,wk 1上升值为 (0 .8± 1.8)kPa ,wk 2为 (1± 3)kPa ,wk 3为 (1.7± 2 .4 )kPa ,wk 4为 (2± 3)kPa ,wk 5为(2 .7± 2 .6 )kPa(P <0 .0 5或P <0 .0 1)。血压增加与疗程增加呈正相关 (r =0 .986 ,P <0 .0 1)。结论 :米多君是一种治疗直立性低血压有效、安全。

AIM: To evaluate the efficacy and safety of midodrine for orthostatic hypotension. METHODS:Twenty-nine patients with primary and secondary orthostatic hypotension participated in a multicenter, self-controlled study. The patients were treated with midodrine 5.0-7.5 mg po, qd for 5 wk. RESULTS: In the 28 evaluable patients, midodrine led to increased orthostatic systolic BP compared to that before treatment at all time points, wk 1(0.8±1.8)kPa (P<0.05); wk 2(1±3)kPa (P<0.05); wk 3 (1.7±2.4)kPa (P<0.01); wk 4 (2±3)kPa (P<0.01); wk 5 (2.7±2.6)kPa (P<0.01). The BP increasing was positively related to the treatment duration. The symptom as dizziness, syncope was improved obviously(P<0.01). CONCLUSION: Midodrine is effective, safe and well-tolerated drug in the treatment of orthostatic hypotension.